Travere Therapeutics Sam.gov Contract For ~$15M Contract Via Dept. Of Veterans Affairs Federal Supply Schedule
https://sam.gov/opp/eac3629bbc3a45ba9533cbfdd5fdecf1/view
60 Biggest Movers From Yesterday
Gainers
NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to expand product portfolio with introduction of Painshield relief for over-the-counter use and plans for future product launch.
SVB Leerink Maintains Outperform on Travere Therapeutics, Raises Price Target to $37
SVB Leerink analyst Joseph Schwartz maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $27 to $37.
Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet
Toward the end of trading Monday, the Dow traded up 0.03% to 35,526.99 while the NASDAQ fell 0.34% to 14,771.91. The S&P also rose, gaining 0.02% to 4,468.88.
Mid-Day Market Update: Crude Oil Down Over 2%; Travere Therapeutics Shares Jump
Midway through trading Monday, the Dow traded down 0.36% to 35,388.46 while the NASDAQ fell 1.24% to 14,639.36. The S&P also fell, dropping 0.54% to 4,443.76.
38 Stocks Moving In Monday’s Mid-Day Session
Gainers
NanoVibronix, Inc. (NASDAQ: NAOV) shares climbed 34.5% to $3.3900 after the company announced plan to expand product portfolio with introduction of Painshield relief for over-the-counter use and plans for future product launch.
Mid-Morning Market Update: Markets Open Lower; Empire State Manufacturing Index Dips In August
Following the market opening Monday, the Dow traded down 0.40% to 35,372.03 while the NASDAQ fell 1.27% to 14,634.24. The S&P also fell, dropping 0.57% to 4,442.47.
Travere Therapeutics Stock Is Trading Higher On Positive Data From Kidney Disease Candidate
Compared to the active control irbesartan, the study met its pre-specified interim primary efficacy endpoint, demonstrating a more than threefold reduction of proteinuria from baseline after 36 weeks of treatment.